Clinical trials
Primary Peritoneal clinical trials
Below are recruiting primary peritoneal clinical trials, each written for real people, not researchers. We’re tracking 83 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05429970Recruiting
Reducing stress before ovarian cancer surgery with two medicines
This study tests whether giving two commonly used medicines before surgery—one that can lower stress on the body (a beta-blocker) and one that reduces inflammation (a COX-2 inhibitor)—can improve outcomes compared with standard care. It’s for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who are having open surgery.
Basking Ridge, New JerseyAges 18 years+ - NCT07480954RecruitingPhase 1/Phase 2
CAR-NK cell therapy for recurrent ovarian cancer
This trial tests a new type of immune cell therapy (CAR-NK cells) that targets two proteins often found on ovarian cancer cells. It is for people whose cancer has come back after at least two prior treatments.
Shenzhen, GuangdongAges 18–75 - NCT05377996RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors with tumor tissue testing
This early-stage study tests emiltatug leda-dotin (Emi-Le) in people with advanced or recurring solid cancers. It aims to see how the drug works and how safely it can be given, using tumor tissue testing to help understand who may benefit.
Phoenix, ArizonaAges 18 years+ - NCT07586826RecruitingPhase 2
Romiplostim N01 plus ATRA for low platelets after cancer treatment
This trial tests a combination of two drugs (romiplostim N01 and ATRA) to help raise platelet counts in people whose platelets dropped after chemotherapy for gynecologic, breast, or lung cancer—even though their cancer is now gone. Low platelets can cause bleeding problems, so this treatment aims to help your body make more platelets.
BeijingAges 18 years+ - NCT07617753RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Recurrent Ovarian Cancer
This trial tests a new type of cell therapy using modified natural killer cells (CAR-NK cells) that are trained to attack ovarian cancer cells. It's designed for patients whose cancer has come back or stopped responding to previous treatments.
Shenzhen, GuangdongAges 18–75 - NCT07667192Recruiting
Re-treating gynecologic cancer with repeat radiation or ablation
This trial studies using additional radiation or tumor-destroying techniques for gynecologic cancer that has come back after previous radiation treatment. It helps doctors understand if this approach is safe and effective for women with recurrent disease.
Zamość, Lublin VoivodeshipAges 18 years+ - NCT06504147RecruitingPhase 2
Radspherin for ovarian cancer with peritoneal spread
This trial tests a radioactive treatment called Radspherin given during surgery for advanced ovarian cancer that has spread to the lining of the abdomen. It is for people whose tumors are HR proficient (a specific genetic type) and who have already had chemotherapy before surgery.
Tampa, FloridaAges 18 years+ - NCT06753136Recruiting
Electrochemotherapy for internal organ tumors
This trial tests a treatment called electrochemotherapy for tumors in internal organs (like the liver or pancreas) when standard treatments are no longer possible. It uses a drug called bleomycin plus electric pulses to target cancer cells.
PadovaAges 18–99 - NCT05755672Recruiting
Study biomarkers during curative-intent treatment for metastatic colon cancer
This study looks at biological markers (substances measured in the body) during treatment for metastatic colorectal cancer. It may help doctors better understand how treatment works, using patients who are treated with a goal of cure.
Lund, Skåne CountyAges 18–110 - NCT06478394Recruiting
Blood test for hidden stomach cancer spread
This study tests a new blood test that uses machine learning to find hidden stomach cancer spread (peritoneal metastases) early. It could help people with locally advanced stomach cancer avoid unnecessary surgery.
Shijiazhuang, HebeiAges 18 years+ - NCT02012699Recruiting
Cancer registry for people with or at risk of cancer
This trial collects health information and samples (a “cancer repository”) to help researchers study cancer and cancer risk. You may be able to join if you’ve had cancer before or if you’re at higher risk or have concerning findings.
Greenwood Village, ColoradoAges 19–110
Hear when a new Primary Peritoneal trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary peritoneal?
- Yes. Clin2 currently lists 83 recruiting primary peritoneal studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary peritoneal trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary peritoneal trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Primary Peritoneal Cancer
- Primary Peritoneal Carcinoma
- Recurrent Primary Peritoneal Carcinoma
- Platinum-Resistant Primary Peritoneal Carcinoma
- Stage IV Primary Peritoneal Cancer AJCC v8
- Primary Peritoneal Endometrioid Adenocarcinoma
- Stage IVA Primary Peritoneal Cancer AJCC v8
- Stage IVB Primary Peritoneal Cancer AJCC v8
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.